Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 8/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.50 |
| ▸ | MAPK6 | Q16659 | 5/20 | 0.50 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31523324 | 1.00 | MAP2K4 (0.50) | MAP2K4MAPK1MAPK6MAPKAPK5ITK | |
| SCHEMBL348514 | 0.81 | MAP2K4 (0.54) | MAP2K4PARP1DYRK1ACSNK2A1KDM4E | |
| SCHEMBL1574004 | 0.81 | MAP2K4 (0.59) | MAP2K4MAPK1MAPK6MAPKAPK5ITK | |
| SCHEMBL922195 | 0.81 | PDPK1 (0.53) | MAP2K4MAPK1MAPK6MAPKAPK5ITK | |
| SCHEMBL4055439 | 0.80 | PARP1 (0.42) | MAP2K4MAPK1MAPK6MAPKAPK5MAPKAPK3 | |
| SCHEMBL1144879 | 0.79 | DYRK1A (0.52) | MAP2K4MAPK1MAPK6MAPKAPK5ITK | |
| SCHEMBL31746650 | 0.79 | DYRK1A (0.52) | MAP2K4MAPK1MAPK6MAPKAPK5ITK | |
| Hydrochloric Acid SCHEMBL17205412 | 0.79 | PDPK1 (0.51) | MAP2K4MAPK1MAPK6MAPKAPK5ITK | |
| SCHEMBL13184207 | 0.79 | MAP2K4 (0.50) | MAP2K4MAPK1MAPK6MAPKAPK5ITK | |
| SCHEMBL13386744 | 0.78 | JAK2 (0.50) | MAP2K4MAPK1MAPK6MAPKAPK5ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| EP-0242167-B1 | HETEROCYCLIC CARBOXAMIDES | ICI AMERICAS INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4898863-A | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1990-02-06 | — | — | US | disclosed |
| CN-87103504-A | Heterocyclic carboxamide | — | 1987-12-09 | — | — | CN | disclosed |
| EP-0242167-A2 | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | MAP2K4 3116/4885MAPK1 492/4885MAPK6 630/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | MAP2K4 3222/4885MAPK1 692/4885MAPK6 730/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | MAP2K4 4725/4885MAPK1 4231/4885MAPK6 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.